| Literature DB >> 25531677 |
Frances Stringer1, Joost DeJongh, Kazuaki Enya, Emiko Koumura, Meindert Danhof, Kohei Kaku.
Abstract
BACKGROUND: This study applied a pharmacodynamic model-based approach to evaluate the long-term durability and glycemic control of pioglitazone in comparison with other oral glucose-lowering drugs in Japanese type 2 diabetes mellitus (T2DM) patients. SUBJECTS AND METHODS: Japanese T2DM patients were enrolled in a prospective, randomized, open-label, blinded-end point study and received pioglitazone with or without other oral glucose-lowering drugs (excluding another thiazolidinedione [TZD]) (n=293) or oral glucose-lowering drugs excluding TZD (n=294). Treatment was adjusted to achieve glycosylated hemoglobin (HbA1c) <6.9%, and samples for fasting plasma glucose (FPG) and HbA1c were collected over 2.5-4 years. A simultaneous cascading indirect response model structure was applied to describe the time course of FPG and HbA1c. HbA1c levels were described using both an FPG-dependent and an FPG-independent function. To account for titration, drug effects for both treatment groups were implemented using a time-dependent Emax model.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25531677 PMCID: PMC4346657 DOI: 10.1089/dia.2014.0222
Source DB: PubMed Journal: Diabetes Technol Ther ISSN: 1520-9156 Impact factor: 6.118